Report Detail

Pharmaceuticals Ocaliva - Drug Insight and Market Forecast - 2030

  • RnM4285760
  • |
  • 12 February, 2021
  • |
  • Global
  • |
  • 30 Pages
  • |
  • DelveInsight
  • |
  • Pharmaceuticals

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Ocaliva
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

    6. Emerging Therapies

      7. Appendix

      Overview
      “ Ocaliva - Drug Insight and Market Forecast - 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Ocaliva in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017 - 2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

      Drug Summary
      Ocaliva is an agonist of the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.
      In May 2016, Intercept Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic acid(UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

      Scope of the report
      The report provides insights into:
      • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
      • Elaborated details on regulatory milestones and other development activities have been provided in this report.
      • The report also highlights the drug marketed details across the United States, Europe and Japan.
      • The report also covers the patents information with expiry timeline around Ocaliva.
      • The report contains historical and forecasted sales for Ocaliva till 2030.
      • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
      • The report also features the SWOT analysis with analyst insights and key findings of Ocaliva.

      Methodology
      The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
      Ocaliva Analytical Perspective by DelveInsight
      • In-depth Ocaliva Market Assessment
      This report provides a detailed market assessment of Ocaliva in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

      • Ocaliva Clinical Assessment
      The report provides the clinical trials information of Ocaliva covering trial interventions, trial conditions, trial status, start and completion dates.

      Report highlights
      • In the coming years, the market scenario for Ocaliva is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
      • The companies and academics are working to assess challenges and seek opportunities that could influence Ocaliva dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
      • Other approved products for the disease are giving market competition to Ocaliva and launch of late-stage emerging therapies in the near future will significantly impact the market.
      • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Ocaliva.
      • Our in-depth analysis of the sales data of Ocaliva from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ocaliva in the market.

      Key Questions
      • What is the prescribed dosage and strengths of Ocaliva are available in the market?
      • What are the common adverse reactions or side effects of Ocaliva?
      • What is the product type, route of administration and mechanism of action of Ocaliva?
      • What are the chemical specifications of Ocaliva?
      • How are the clinical trials diversified on the basis of the trial status?
      • What is the history of Ocaliva, and what is its future?
      • What are the marketed details of Ocaliva in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
      • How many patents have been granted to Ocaliva and when these patents will get expire?
      • What are the pros (benefits) and cons (disadvantages) of Ocaliva?
      • In which countries Ocaliva got approval and when it gets launched?
      • What are the clinical trials are currently ongoing for Ocaliva?
      • How the safety and efficacy results determined the approval of Ocaliva?
      • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ocaliva development?
      • What are the key designations that have been granted to Ocaliva?
      • What is the historical and forecasted market scenario of Ocaliva?
      • How is the market trend of Ocaliva is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
      • What are the other approved products available and how these are giving competition to Ocaliva?
      • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?


      Summary:
      Get latest Market Research Reports on Ocaliva. Industry analysis & Market Report on Ocaliva is a syndicated market report, published as Ocaliva - Drug Insight and Market Forecast - 2030. It is complete Research Study and Industry Analysis of Ocaliva market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,750.00
      $5,500.00
      $8,250.00
      1,970.82
      3,941.64
      5,912.46
      2,278.18
      4,556.36
      6,834.54
      293,859.50
      587,719.00
      881,578.50
      201,898.95
      403,797.90
      605,696.85
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report